| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. | J Clin Oncol | 2011 | 4.81 |
| 2 | Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. | J Natl Cancer Inst | 2013 | 2.28 |
| 3 | Advances in adjuvant therapy for breast cancer. | Clin Adv Hematol Oncol | 2006 | 0.94 |
| 4 | Should Histologic Grade Be Incorporated into the TNM Classification System for Small (T1, T2) Node-Negative Breast Adenocarcinomas? | Patholog Res Int | 2010 | 0.76 |
| 5 | Reply to V. Pitini et al. | J Clin Oncol | 2013 | 0.75 |
| 6 | Systemic therapy for HER2-positive early-stage breast cancer. | Curr Probl Cancer | 2016 | 0.75 |